DCT

2:26-cv-06218

Shionogi Inc v. Lupin Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-06218, D.N.J., 05/28/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Lupin Limited is a foreign corporation, and Defendant Lupin Pharmaceuticals has a regular and established place of business in the district, has committed acts of infringement in the district, and has previously consented to venue in the district in other litigation.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the drug RADICAVA ORS® constitutes an act of infringement of a patent directed to methods of administering an oral formulation of edaravone.
  • Technical Context: The technology relates to pharmaceutical treatment for Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease, by providing a specific oral administration regimen for the drug edaravone that manages food-effect variability on drug absorption.
  • Key Procedural History: This is a Hatch-Waxman action triggered by Defendants' filing of ANDA No. 219415 with a Paragraph IV certification, asserting non-infringement of the patent-in-suit. The drug at issue, RADICAVA ORS®, was granted seven years of Orphan Drug Exclusivity by the FDA. The plaintiff, Shionogi Inc., recently acquired the RADICAVA ORS® business and associated patents from Tanabe Pharma Corporation. The complaint notes numerous other pending infringement actions in the same district related to the same drug.

Case Timeline

Date Event
2020-11-12 '469 Patent Priority Date
2022-05-12 FDA grants approval for RADICAVA ORS® (NDA No. 215446)
2022-09-01 Lupin Pharmaceuticals submits FOIA request for RADICAVA ORS® data
2024-03-28 FDA grants Orphan Drug Exclusivity for RADICAVA ORS®
2025-12-22 Shionogi publicly announces agreement to acquire RADICAVA ORS® business
2026-03-10 U.S. Patent No. 12,569,469 issues
2026-04-01 Shionogi completes acquisition of RADICAVA ORS® assets
2026-04-13 Lupin sends Paragraph IV Notice Letter regarding ANDA No. 219415
2026-05-28 Complaint for Patent Infringement filed
2029-05-12 Orphan Drug Exclusivity for RADICAVA ORS® expires

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,569,469 - "Pharmaceutical composition for oral administration of edaravone and method of administering same"

  • Patent Identification: U.S. Patent No. 12,569,469 ("the '469 patent"), "Pharmaceutical composition for oral administration of edaravone and method of administering same," issued March 10, 2026 Compl. ¶38 '469 Patent, front page

The Invention Explained

  • Problem Addressed: The active ingredient edaravone is a treatment for the neurodegenerative disease ALS but was previously available only as an injectable agent Compl. ¶11 '469 Patent, col. 1:65-col. 2:2 While an oral formulation is more convenient, the inventors found that consumption of meals prior to administration significantly and variably impacts the drug's pharmacokinetics, potentially reducing its efficacy '469 Patent, col. 15:45-53
  • The Patented Solution: The '469 patent discloses a method for administering an oral edaravone composition that avoids the negative food effect by implementing specific time intervals between meal consumption and drug administration '469 Patent, abstract The invention specifies distinct waiting periods depending on whether the patient consumed a high-fat, standard, or light meal, thereby ensuring consistent drug absorption and bioavailability similar to administration in a fasted state '469 Patent, col. 17:3-13 '469 Patent, cl. 1
  • Technical Importance: This dosing regimen enables the use of a convenient oral suspension for ALS patients, reducing the significant burden associated with intravenous infusions for patients and caregivers Compl. ¶¶11-12

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the '469 patent, including at least Independent Claim 1 Compl. ¶47
  • The essential elements of Independent Claim 1, a method of treating ALS, include:
    • Orally or intragastrically administering a liquid pharmaceutical composition comprising edaravone.
    • Observing a "first time interval" between the consumption of a meal and the administration of the drug.
    • The specific "first time interval" is defined based on the meal type: 8 hours for a high-fat meal, 4 hours for a low-fat meal, or 2 hours for a caloric supplement.
    • The administration timing is performed "such that" the resulting maximum drug concentration (Cmax) decreases by less than 20% and/or the total drug exposure (AUC) decreases by less than 10% compared to administration in a fasted state.
    • Observing a "second time interval" of at least 1 hour from the administration of the drug to the consumption of the next meal.
      '469 Patent, cl. 1

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendants' proposed generic edaravone oral suspension, for which Defendants submitted ANDA No. 219415 to the FDA Compl. ¶¶19, 39

Functionality and Market Context

The complaint alleges that the accused product is a proposed generic copy of Plaintiff's RADICAVA ORS® product Compl. ¶42 It is an oral suspension of edaravone with a proposed dose concentration of 105 mg/5 mL Compl. ¶40 The complaint asserts that RADICAVA ORS® is a major contribution to patient care for ALS because it provides a clinically superior oral administration option compared to the previously available intravenous formulation Compl. ¶12 Defendants seek approval to market their generic version prior to the expiration of the '469 patent Compl. ¶42

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint does not contain a detailed claim chart. The infringement theory is based on the act of filing the ANDA under 35 U.S.C. § 271(e)(2) and inducement of infringement under 35 U.S.C. § 271(b) Compl. ¶¶48-49 The allegation is that the proposed labeling for Defendants' generic product will instruct physicians and patients to administer the drug according to a regimen that meets the limitations of the asserted claims Compl. ¶48

'469 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating amyotrophic lateral sclerosis, comprising: orally or intragastrically administering... a liquid pharmaceutical composition comprising edaravone... The filing of ANDA No. 219415 seeks approval for a proposed edaravone oral suspension, and the proposed labeling is alleged to instruct its administration to treat ALS. ¶40; ¶42; ¶48 col. 45:4-8
...with a first time interval from a consumption of a meal... wherein the first time interval for the consumption of a high-fat meal... is 8 hours... the first time interval for the consumption of a low-fat meal... is 4 hours... or the first time interval for... a caloric supplement... is 2 hours... The proposed labeling for the generic product is alleged to instruct, encourage, and/or promote administration according to the claimed time intervals between various meal types and drug intake. ¶48 col. 45:9-25
...such that a decrease in Cmax is less than 20%... and/or that a decrease in AUC is less than 10% with respect to... fasting... The complaint alleges that administration according to the proposed label performs substantially the same function in substantially the same way to obtain the same result as the patented method. ¶47 col. 45:26-33
...and the second time interval from the administration of the liquid pharmaceutical composition to the consumption of the next meal... is 1 hour. The proposed labeling for the generic product is alleged to instruct, encourage, and/or promote waiting at least one hour after administration before consuming the next meal. ¶48 col. 45:34-39
  • Identified Points of Contention:
    • Scope Questions: A central dispute may be whether the instructions in Defendants' proposed labeling will direct or encourage users to perform each and every step of the claimed method. The infringement analysis will question if following the label necessarily results in practicing the claimed time intervals for the specific meal types defined in the patent.
    • Technical Questions: The claim includes a functional limitation regarding the resulting pharmacokinetic profile (Cmax and AUC). A point of contention may be whether Defendants' specific formulation, even when administered according to the label instructions, actually achieves this claimed pharmacokinetic outcome.

V. Key Claim Terms for Construction

  • The Term: "a high-fat meal," "a low-fat meal," "a caloric supplement"

    • Context and Importance: These terms define the conditions that trigger the specific administration timing requirements of Claim 1. The precise scope of these definitions is critical to determining what patient actions, as instructed by the accused product's label, constitute infringement.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification uses the term "for example" when introducing the meal classifications, which may suggest the definitions are illustrative rather than exhaustive '469 Patent, col. 17:3-6
      • Evidence for a Narrower Interpretation: Claim 1 itself provides explicit quantitative definitions for each meal type (e.g., "a high-fat meal in a range of 800 to 1000 calories with 50% fat") '469 Patent, cl. 1 The specification provides further detailed examples and criteria that align with these quantitative limits, which a party could argue confines the terms to these specific ranges '469 Patent, col. 18:40-63

  • The Term: "such that a decrease in Cmax is less than 20%... and/or that a decrease in AUC is less than 10%"

    • Context and Importance: This functional, result-oriented language is a crucial limitation. To prove infringement, the plaintiff must show not only that the administration steps are performed, but also that this specific pharmacokinetic result is achieved. Practitioners may focus on this term as a potential basis for both non-infringement and invalidity arguments.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent specification includes extensive experimental data in tables and figures demonstrating that administration according to the claimed time intervals yields this pharmacokinetic result '469 Patent, Tables 2-4 '469 Patent, FIG. 1 A party may argue that this data shows the result is an inherent property of performing the claimed steps.
      • Evidence for a Narrower Interpretation: A party could argue that this limitation renders the claim indefinite under 35 U.S.C. § 112 because a person of ordinary skill in the art cannot, without undue experimentation, readily determine whether a particular act of administration meets the claimed pharmacokinetic profile. The variability shown in the patent's own data could be cited to support this argument '469 Patent, FIG. 1

VI. Other Allegations

  • Indirect Infringement: The complaint alleges active inducement of infringement under 35 U.S.C. § 271(b) Compl. ¶48 The factual basis is the allegation that Defendants' proposed product labeling will instruct, encourage, and promote administration of the edaravone suspension by physicians and patients in a manner that directly infringes at least Claim 1 of the '469 patent Compl. ¶48 The complaint further alleges that Defendants possess the specific intent to induce this infringement Compl. ¶52
  • Willful Infringement: The complaint alleges that Defendants were aware of the '469 patent prior to amending their ANDA to include a Paragraph IV certification Compl. ¶52 It further alleges that Defendants' submission of the ANDA was made "despite an objectively high likelihood that its submission constituted infringement of a valid patent, and this risk was either known to Lupin or so obvious that it should have been known," which tracks the legal standard for willful infringement Compl. ¶52

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of induced infringement: Can Shionogi prove that the language on Lupin's proposed product label, which has not yet been made public, will be specific enough to demonstrate an affirmative intent to encourage or instruct physicians and patients to practice the patented method? The outcome will likely depend on whether the label's directions are mandatory or merely suggestive, and how closely they track the patent's specific meal-and-timing limitations.
  • A second key issue will be claim scope and validity: The infringement and validity of the asserted method claim will turn on the construction of its functional pharmacokinetic limitation ("such that a decrease in Cmax..."). The case will raise the evidentiary question of whether Lupin's proposed formulation achieves this result, and the legal question of whether this type of functional language renders the claim indefinite and therefore invalid.
  • A final question relates to the statutory act of infringement: As an ANDA case, the primary act of infringement is the filing of the application itself. A central battleground will be the comparison of the scope of the patent claims to the product that Lupin's ANDA seeks to market, as will be defined by its proposed labeling and bioequivalence data.
Loading Complaint